Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05279053
Other study ID # 17-000387
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 1, 2021
Est. completion date March 31, 2023

Study information

Verified date August 2023
Source University of California, Los Angeles
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The proposed study will evaluate sex differences in whole-brain glutamate (Glu), with a focus on the dorsal anterior cingulate cortex (dACC), anterior insula, and thalamus, as well as how it is influenced by sex (males vs. females), smoking state (overnight abstinent vs. sated), and circulating ovarian hormones (estrogen and progesterone) in women. Glu will be measured in almost the entire brain, with special focus on the dorsal anterior cingulate cortex (dACC), anterior insula, and thalamus, all of which have been implicated in behavioral states linked to tobacco withdrawal, using an echo-planar spectroscopic imaging (EPSI) variant of magnetic resonance spectroscopy (MRS). Serum ovarian hormones (estrogen and progesterone) will be measured for female participants to determine relationships between brain Glu and this hormone. Whole-brain Glu will be measured in 60 smokers (30 men, 30 women) twice, after overnight (~12 h) abstinence and after participants smoke the first cigarette of the day.


Recruitment information / eligibility

Status Completed
Enrollment 58
Est. completion date March 31, 2023
Est. primary completion date March 31, 2023
Accepts healthy volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: 1. Self-identified as only male or female 2. Age 18-45 years (children <18 years will be excluded due to low prevalence of conventional cigarette smoking; female participants >45 years of age will be excluded to avoid effects of perimenopause and menopause in women; male participants >45 years of age will be excluded as well to ensure that male and female groups are matched on age 3. English fluency demonstrated by verbal skills sufficient to participate in a conversation, including the ability to ask and answer questions at a level that assures adequate understanding of the study (a comprehension quiz will be given) 4. Right handedness (evaluated using the Edinburgh Inventory) 5. Generally in good health without cardiovascular, hepatic, renal, or autoimmune diseases, diabetes, or cancer 6. Must have smoked for =1 year 7. Must endorse inhaling while smoking 8. Must smoke =10 cigarettes per day 9. Must have expired CO >10 ppm and urinary cotinine =100 ng/ml at screening/intake 10. Fulfillment of DSM-5 criteria for Tobacco Use Disorder Exclusion Criteria: 1. Seeking treatment for nicotine dependence within 3 months of screening 2. Medical condition that may compromise safety (based on history, physical exam) 3. Neurological disorder that would compromise compliance and/or informed consent 4. Major psychiatric disorder (e.g., Major Depression, Schizophrenia, Bipolar Disorder) per DSM-5 MINI 5. Current drug use disorders other than Tobacco Use Disorder (as defined in DSM-5) 6. Recent use of cocaine, opiates, benzodiazepines, or amphetamines as shown by urine test at the screening or testing sessions 7. Smoke marijuana >3X/week (self-report) or positive marijuana urine test on a scan day (positive at screening allowed) 8. Use of tobacco in forms other than cigarettes (e.g., snuff, chewing tobacco, e-cigarettes) >10 days in the month before screening 9. Preference for menthol cigarettes, given sex differences in the effect of menthol on the rate of nicotine entry into the brain 10. Pregnancy or nursing 11. Presence in the body of metal that would compromise safety during MRI 12. Claustrophobia 13. Any other condition that would compromise safety

Study Design


Locations

Country Name City State
United States UCLA Semel Institute Los Angeles California

Sponsors (1)

Lead Sponsor Collaborator
University of California, Los Angeles

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Circulating Ovarian Hormone: Estrogen - in overnight abstinent smokers Estrogen assayed via a blood sample Measured before and after smoking a cigarette across a period of 2 hours
Primary Circulating Ovarian Hormone: Progesterone - in overnight abstinent smokers Estrogen assayed via a blood sample Measured before and after smoking a cigarette across a period of 2 hours
Primary Whole Brain Glutamate Measured by EPSI acquisition in overnight abstinent smokers Measured before and after smoking a cigarette across a period of 2 hours
Primary Nicotine Metabolite Ratio Measured by blood sample Measured before smoking a cigarette at a single timepoint
Secondary Urge to Smoke Scale (UTS) This is a 10-item self-reporting questionnaire that measures cigarette craving Measured before and after smoking a cigarette across a period of 2 hours
Secondary Shiffman-Jarvik Withdrawal Scale (SJWS) This is a 25-item self-reporting questionnaire that measures psychological withdrawal Measured before and after smoking a cigarette across a period of 2 hours
Secondary Positive and Negative Affect Schedule (PANAS) This is a 20-item self-reporting questionnaire that measures positive and negative affect Measured before and after smoking a cigarette across a period of 2 hours
Secondary Spielberger State-Trait Anxiety (STAI) This is a 20-item self-reporting questionnaire that measures anxiety Measured before and after smoking a cigarette across a period of 2 hours
See also
  Status Clinical Trial Phase
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Active, not recruiting NCT02643914 - Control Systems Approach to Predicting Individualized Dynamics of Nicotine Cravings N/A
Recruiting NCT02422914 - Benefits of Tobacco Free Cigarette N/A
Active, not recruiting NCT02629679 - Sports, Education and Consumption of Substances in Adolescents N/A
Completed NCT02218281 - Developing a Smartphone App With Mindfulness Training for Teen Smoking Cessation N/A
Completed NCT02385227 - Characterization of Biomarkers of Tobacco Exposure, Urge-to-Smoke Following Exclusive and Dual Ad Lib Use of Electronic Cigarettes N/A
Completed NCT01199380 - Behavioral Activation Intervention for Smoking Cessation in Smokers With Depressive Symptoms Phase 2
Completed NCT00802919 - Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors Phase 4
Completed NCT01692353 - Cardiovascular Disease Biomarkers in Smokers and Moist Snuff Consumers N/A
Completed NCT01081119 - Brief Voluntary Alcohol and Drug Intervention for Middle School Youth Phase 2
Completed NCT00756704 - The Effectiveness of Smoking Cessation Guidelines in the Emergency Department N/A
Completed NCT00682474 - School Nurse-Delivered Smoking Cessation Intervention Phase 2/Phase 3
Completed NCT05520775 - Semaglutide for Alcohol Use Disorder Phase 2
Completed NCT03743532 - E-Cigarettes and Financial Incentives to Promote Tobacco Harm Reduction Among Adults Accessing Shelter Services N/A
Terminated NCT03840694 - Nicotine Withdrawal and Reward Processing: Connecting Neurobiology to Real-world Behavior N/A
Completed NCT06032793 - Effects of Deep Breathing Exercise on Pulmonary Function, Perceived Stress and Physical Fitness. N/A
Terminated NCT03326128 - High Dose Bupropion for Smoking Cessation - Pilot Study Phase 2
Recruiting NCT03218670 - Your Health in On Click N/A
Completed NCT02538042 - Strengthening Instrumental Extinction to Prevent Smoking Relapse (VLNCCue) N/A